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Abstract:
Retrospective prescribing data were obtained from 46 general practice surgeries in 
Main text: INTRODUCTION:
Management of chronic asthma in the United Kingdom (UK) is guided by a step-wise approach recommended by the British Thoracic Society and Scottish Intercollegiate Guideline Network (BTS/SIGN) guideline. [1] Combination therapy with an inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) is the preferred treatment at step 3, when the use of an ICS alone is insufficient for the control of persistent asthma, which is defined by the presence of symptoms, their effect on the patient's quality of life, and the future risk of adverse events such as exacerbation. [1] Previously, escalation of ICS dose was advocated to achieve optimal control, however, major international guidelines now agree on the therapeutic benefits of adding LABA therapy to ICS therapy.
The appropriate use of combination therapy has also been questioned. Breton, et al.
described the prescribing of combination therapy against the current Canadian asthma guidelines and found that only 40% of patients prescribed combination therapy had received a prescription for an ICS in the preceding year. [2] However, no analyses to our knowledge have described ICS dose transitions on initiation of combination therapy in patients in general practice. The aim of this study was to describe dose changes during the transition from ICS to newly initiated combination inhaler therapy in patients with asthma.
METHODS:
A retrospective database analysis was conducted in 46 practices (~80% coverage) in of age, low-dose ICS was defined as ≤400 micrograms daily, medium-dose ICS as >400 micrograms daily and ≤800 micrograms daily and high-dose as ICS >800 micrograms daily: for patients ≤12 years old, the dose cut-offs were halved. [1] Patients were assessed according to highest ICS dose they received in the year before the index date and the first dose of ICS in the combination therapy inhaler they received on the index date. Sensitivity analyses excluding patients with comorbid COPD and looking specifically at children were also performed. The use of SABA and OCS in the year before the index date were quantified as markers of asthma symptoms and exacerbations, respectively.
RESULTS:
685 patients initiated combination inhaler therapy during the study period. The majority of patients were women (403; 58.8%) with a median age of 47 years 
DISCUSSION:
This analysis demonstrates significant use of high-dose combination therapy among patients with asthma treated in GP surgeries. Widespread use of high-dose ICS in the UK has been noted previously. Thomas et al. found that within a prescribing analysis of over 22,000 adults/adolescents with asthma, 27% of patients received high-dose ICS, and 83.6% of them had no record of a trial of add-on therapy with a LABA or other controller therapy. [3] The present analysis found that over threequarters of patients received ICS therapy before starting therapy with a combination inhaler, suggestive of better concordance with guideline recommendations.
However, upon addition of a LABA to the therapy regimen, there was a widespread pattern of simultaneous ICS dose escalation, with patients advancing directly to highdose combination therapy, largely irrespective of their baseline ICS dose. This suggests not only questionable use of high-dose ICS, but also failure to follow guideline recommendations.
The dose-response relationship of ICS has been the subject of much research, although high quality evidence indicates that the therapeutic benefits of ICS are seen at doses of 200-1000 mcg BDP-equivalent daily. [4] [5] Above this threshold, adverse effects of ICS such as HPA-axis suppression, osteoporosis and skin bruising are more common. Accordingly, the wide utilisation of high-dose ICS is likely to produce a poor return on investment, with an increased risk of local and systemic adverse effects traded for little gain in asthma control. Although as a database analysis, we were unable to determine the clinical reasoning underlying ICS dose changes, the patterns noted in this study should prompt further investigation into the appropriateness of high-dose ICS prescribing in UK general practice.
Fluticasone/salmeterol was most commonly used high-dose combination therapy in this analysis, but the reasons behind this are unclear. Fluticasone may be preferentially chosen for treatment due to its potency and ease of dosing regimen to achieve higher doses. A post hoc analysis found that of the 488 patients prescribed high-dose combination therapy, 149 (30.5%) were prescribed doses ≥1600 mcg daily ("very high-dose ICS"), and all but 5 of these patients received fluticasone/salmeterol. However, we also acknowledge that this prescribing may be inadvertent, and that a lack of awareness of potency differences between different ICS preparations may lead to the product being prescribed at twice the intended dose of budesonide/formoterol. Another contributing factor may be the licensing of high-dose combination therapy for the treatment of COPD. The analysis included patients with co-morbid COPD in the analysis, as this group of patients is often excluded from randomised controlled trials, despite constituting 5-20% of the asthma population. While it would be plausible that the inclusion of this patient group would inflate the use of high-dose combination therapy, the results of our sensitivity analysis showed no differences from the full cohort. However, clinicians may feel more comfortable prescribing larger doses of ICS for asthma than previously due to widespread use of high-dose ICS in COPD, and may alter their prescribing practices for patients with asthma.
There was no discernible pattern of SABA/OCS prescribing among ICS dose categories, suggesting that patient symptoms and/or exacerbations were not primary motivators for dose increases during the initiation of combination inhaler therapy in this analysis. While symptoms and/or exacerbations may push a clinician to escalate therapy rapidly, changing a patient from no ICS therapy to high-dose combination therapy remains concerning and there is little evidence to support this approach. Our analysis did uncover some ICS dose step-down, albeit with the concurrent addition of a LABA (medium-dose ICS changed to low-dose combination inhaler). Although this was only seen in a small number of patients, it may provide some reassurance to the use of increasing doses of ICS and combination therapy.
High-dose combination inhalers were prescribed frequently in this UK cohort with asthma, even without a history of ICS treatment. Evaluation of the appropriateness of high-dose prescribing in general practice is needed and educational efforts should focus on the dose-response relationship of ICS and the risk of adverse effects when using high-dose ICS.
Acknowledgements: The authors thank the NHS Forth Valley Airways Managed
Clinical Network for provision of the data.
Contributorship: ACB, FW and JRC were responsible for the concept of the study, BFJ for the analytical methods and JRC for handling of the data and execution of the analysis. All authors interpreted the data, wrote the manuscript, had access to the data and made the decision to submit for publication. ACB is the guarantor.
Transparency declaration:
The guarantor affirms that this manuscript is an honest, accurate and transparent account of the study being reported, that no important aspects of the study have been omitted and that any discrepancies from the study as planned have been explained.
Ethical approval:
Departmental ethics was consulted regarding use of the database and determined that no formal review was required. 
